{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:03:46Z","timestamp":1781625826341,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204544"],"award-info":[{"award-number":["82204544"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40262-026-01647-z","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:20:32Z","timestamp":1777432832000},"page":"883-895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetics of Sacubitril\/Valsartan in Patients with Heart Failure and End-Stage Renal Disease Undergoing Peritoneal Dialysis"],"prefix":"10.1007","volume":"65","author":[{"given":"Ying","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3295-619X","authenticated-orcid":false,"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"1647_CR1","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.kisu.2020.09.001","volume":"10","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zhao MH, Zuo L, Wang Y, Yu F, Zhang H, et al. China Kidney Disease Network (CK-NET) 2016 annual data report. Kidney Int Suppl. 2020;10:e97-185.","journal-title":"Kidney Int Suppl"},{"key":"1647_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease: a systematic review and meta-analysis. PLoS ONE. 2016;11:e0158765.","journal-title":"PLoS ONE"},{"key":"1647_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339\u201352.","journal-title":"Lancet"},{"key":"1647_CR4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41581-022-00623-7","volume":"18","author":"AK Bello","year":"2022","unstructured":"Bello AK, Okpechi IG, Osman MA, Cho Y, Cullis B, Htay H, et al. Epidemiology of peritoneal dialysis outcomes. Nat Rev Nephrol. 2022;18:779\u201393.","journal-title":"Nat Rev Nephrol"},{"key":"1647_CR5","doi-asserted-by":"publisher","first-page":"38768","DOI":"10.1038\/srep38768","volume":"6","author":"W Zhang","year":"2016","unstructured":"Zhang W, Shi W, Liu Z, Gu Y, Chen Q, Yuan W, et al. A nationwide cross-sectional survey on prevalence, management and pharmacoepidemiology patterns on hypertension in Chinese patients with chronic kidney disease. Sci Rep. 2016;6:38768.","journal-title":"Sci Rep"},{"key":"1647_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","volume":"50","author":"J Gu","year":"2010","unstructured":"Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401\u201314.","journal-title":"J Clin Pharmacol"},{"key":"1647_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/phar.2075","volume":"38","author":"KR Smith","year":"2018","unstructured":"Smith KR, Hsu CC, Berei TJ, Aldemerdash A, Hollis IB, Vardeny O, et al. PARADIGM-HF trial: secondary analyses address unanswered questions. Pharmacotherapy. 2018;38:284\u201398.","journal-title":"Pharmacotherapy"},{"key":"1647_CR8","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","volume":"138","author":"R Haynes","year":"2018","unstructured":"Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, et al. Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease. Circulation. 2018;138:1505\u201314.","journal-title":"Circulation"},{"key":"1647_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jchf.2020.08.014","volume":"9","author":"KS Jering","year":"2021","unstructured":"Jering KS, Zannad F, Claggett B, McCausland FR, Ferreira JP, Desai A, et al. Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF. JACC Heart Fail. 2021;9:13\u201324.","journal-title":"JACC Heart Fail."},{"key":"1647_CR10","doi-asserted-by":"publisher","first-page":"2349135","DOI":"10.1080\/0886022X.2024.2349135","volume":"46","author":"X Yang","year":"2024","unstructured":"Yang X, Jin J, Cheng M, Xu J, Bai Y. The role of sacubitril\/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis. Ren Fail. 2024;46:2349135.","journal-title":"Ren Fail"},{"issue":"11","key":"1647_CR11","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamacardio.2024.2566","volume":"9","author":"H Lu","year":"2024","unstructured":"Lu H, Claggett BL, Packer M, Lam CSP, Swedberg K, Rouleau J, et al. Effects of sacubitril\/valsartan on all-cause hospitalizations in heart failure: post hoc analysis of the PARADIGM-HF and PARAGON-HF randomized clinical trials. JAMA Cardiol. 2024;9(11):1047\u201352.","journal-title":"JAMA Cardiol."},{"key":"1647_CR12","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1093\/ndt\/gfad038","volume":"38","author":"Y He","year":"2023","unstructured":"He Y, Jin Y, Xue H, Liu R, Zhang M, Liao R, et al. Pharmacokinetics and pharmacodynamics of sacubitril\/valsartan in peritoneal dialysis patients. Nephrol Dial Transplant. 2023;38:1880\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1647_CR13","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s40262-017-0543-3","volume":"56","author":"S Ayalasomayajula","year":"2017","unstructured":"Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Clinical pharmacokinetics of sacubitril\/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor. Clin Pharmacokinet. 2017;56:1461\u201378.","journal-title":"Clin Pharmacokinet"},{"key":"1647_CR14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44:1051\u201365.","journal-title":"Clin Pharmacokinet"},{"key":"1647_CR15","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s40262-020-00883-1","volume":"59","author":"J Sinha","year":"2020","unstructured":"Sinha J, Al-Sallami HS, Duffull SB. An extension of Janmahasatian\u2019s fat-free mass model for universal application across populations of different ethnicities. Clin Pharmacokinet. 2020;59:1161\u201370.","journal-title":"Clin Pharmacokinet"},{"key":"1647_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/cpdd.1181","volume":"12","author":"H Yang","year":"2023","unstructured":"Yang H, Gao R, Ji X, Wang Z, Qiu W. Population pharmacokinetic analysis of valsartan in healthy Chinese subjects. Clin Pharmacol Drug Dev. 2023;12:249\u201356.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1647_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/1755-5922.12183","volume":"34","author":"Z Kobalava","year":"2016","unstructured":"Kobalava Z, Kotovskaya Y, Averkov O, Pavlikova E, Moiseev V, Albrecht D, et al. Pharmacodynamic and pharmacokinetic profiles of sacubitril\/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction. Cardiovasc Ther. 2016;34:191\u20138.","journal-title":"Cardiovasc Ther"},{"key":"1647_CR18","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/psp4.12829","volume":"11","author":"JF Marier","year":"2022","unstructured":"Marier JF, Teuscher N, Mouksassi MS. Evaluation of covariate effects using forest plots and introduction to the coveffectsplot R package. CPT Pharmacomet Syst Pharmacol. 2022;11:1283\u201393.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1647_CR19","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.3390\/jcm12186105","volume":"12","author":"A Xanthopoulos","year":"2023","unstructured":"Xanthopoulos A, Papamichail A, Briasoulis A, Loritis K, Bourazana A, Magouliotis DE, et al. Heart failure in patients with chronic kidney disease. J Clin Med. 2023;12:6105.","journal-title":"J Clin Med"},{"key":"1647_CR20","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1136\/heartjnl-2016-310913","volume":"103","author":"S Carlson","year":"2017","unstructured":"Carlson S, Duber HC, Achan J, Ikilezi G, Mokdad AH, Stergachis A, et al. Capacity for diagnosis and treatment of heart failure in sub-Saharan Africa. Heart. 2017;103:1874\u20139.","journal-title":"Heart"},{"key":"1647_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2133\/dmpk.24.145","volume":"24","author":"B Habtemariam","year":"2009","unstructured":"Habtemariam B, Sallas W, Sunkara G, Kern S, Jarugula V, Pillai G. Population pharmacokinetics of valsartan in pediatrics. Drug Metab Pharmacokinet. 2009;24:145\u201352.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1647_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s13318-016-0328-3","volume":"42","author":"Y Han","year":"2017","unstructured":"Han Y, Ayalasomayajula S, Pan W, Yang F, Yuan Y, Langenickel T, et al. Pharmacokinetics, safety and tolerability of sacubitril\/valsartan (LCZ696) after single-dose administration in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 2017;42:109\u201316.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1647_CR23","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1111\/bph.16504","volume":"181","author":"H Yu","year":"2024","unstructured":"Yu H, Greasley PJ, Lambers Heerspink HJ, Ambery P, Ahlstrom C, Hamren B, et al. The role of venous capacity in fluid retention with endothelin A antagonism: mathematical modelling of the RADAR trial. Br J Pharmacol. 2024;181:4693\u2013707.","journal-title":"Br J Pharmacol"},{"key":"1647_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/HJH.0000000000003972","volume":"43","author":"DV Nguyen","year":"2025","unstructured":"Nguyen DV, Pham GT, Pham SN, Nguyen HTT. Efficacy and safety of sacubitril-valsartan in hypertension patients with end-stage kidney disease on maintenance dialysis: a meta-analysis. J Hypertens. 2025;43:557\u201367.","journal-title":"J Hypertens"},{"key":"1647_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026407","volume":"11","author":"CY Niu","year":"2022","unstructured":"Niu CY, Yang SF, Ou SM, Wu CH, Huang PH, Hung CL, et al. Sacubitril\/valsartan in patients with heart failure and concomitant end-stage kidney disease. J Am Heart Assoc. 2022;11:e026407.","journal-title":"J Am Heart Assoc"},{"key":"1647_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/jcph.571","volume":"56","author":"L Gan","year":"2016","unstructured":"Gan L, Langenickel T, Petruck J, Kode K, Rajman I, Chandra P, et al. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J Clin Pharmacol. 2016;56:78\u201386.","journal-title":"J Clin Pharmacol"},{"key":"1647_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/(SICI)1099-081X(199805)19:4<237::AID-BDD100>3.0.CO;2-7","volume":"19","author":"A Sioufi","year":"1998","unstructured":"Sioufi A, Marfil F, Jaouen A, Cardot JM, Godbillon J, Ezzet F, et al. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos. 1998;19:237\u201344.","journal-title":"Biopharm Drug Dispos"},{"key":"1647_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/cpdd.183","volume":"4","author":"HL Hsiao","year":"2015","unstructured":"Hsiao HL, Langenickel TH, Greeley M, Roberts J, Zhou W, Pal P, et al. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol. Clin Pharmacol Drug Dev. 2015;4:407\u201317.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1647_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/cpdd.181","volume":"5","author":"L Gan","year":"2016","unstructured":"Gan L, Jiang X, Mendonza A, Swan T, Reynolds C, Nguyen J, et al. Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects. Clin Pharmacol Drug Dev. 2016;5:27\u201339.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1647_CR30","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00228-016-2072-7","volume":"72","author":"SP Ayalasomayajula","year":"2016","unstructured":"Ayalasomayajula SP, Langenickel TH, Jordaan P, Zhou W, Chandra P, Albrecht D, et al. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril\/valsartan), an angiotensin receptor neprilysin inhibitor. Eur J Clin Pharmacol. 2016;72:1065\u201373.","journal-title":"Eur J Clin Pharmacol"},{"key":"1647_CR31","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/ndt\/gfad066","volume":"38","author":"PK Judge","year":"2023","unstructured":"Judge PK, Herrington WG, Haynes R. Sacubitril\/valsartan in peritoneal dialysis-lessons from a pharmacokinetic study. Nephrol Dial Transplant. 2023;38:1780\u20131.","journal-title":"Nephrol Dial Transplant"},{"key":"1647_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejps.2018.03.031","volume":"118","author":"L Ngo","year":"2018","unstructured":"Ngo L, Cho HY, Lee YB. Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: population model-based approach. Eur J Pharm Sci. 2018;118:154\u201364.","journal-title":"Eur J Pharm Sci"},{"key":"1647_CR33","unstructured":"US Food and Drug Administration. Entresto (sacubitril and valsartan) prescribing information. Silver Spring (MD): FDA; 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218591Orig1s000,207620Orig1s025lbl.pdf. Accessed 13 Feb 2026."},{"key":"1647_CR34","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.jacc.2022.08.737","volume":"80","author":"R Mohebi","year":"2022","unstructured":"Mohebi R, Liu Y, Pi\u00f1a IL, Prescott MF, Butler J, Felker GM, et al. Dose-response to sacubitril\/valsartan in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2022;80:1529\u201341.","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01647-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01647-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01647-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:07:21Z","timestamp":1781622441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01647-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1647"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01647-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ying Jin, Nuo Xu, Wenyu Yang, Bijue Liu, Runhan Liu, Yufei Shi, Mengyu Zhang, Xiaoqiang Xiang, Zhenlei Wang, and Xiao Zhu have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The clinical study (Chinese Clinical Trial No.: ChiCTR2200055924) protocol was approved by the Ethics Committee for Biomedical Review of West China Hospital of Sichuan University [No. 2021 (1712)], in accordance with the Declaration of Helsinki and International Ethical Guidelines for Human Biomedical Research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written consent prior to participating in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data generated and\/or analyzed during the current study are available fromZhenglei Wang or Xiao Zhu on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"WZL and XZ conceptualized the study. JY, LRH, ZMY, and WZL collected the data. XN, YWY, LBJ, XXQ, and XZ analyzed the data. JY, XN, and XZ drafted the first version of the manuscript. All authors contributed to the intellectual content of the manuscript and approved the manuscript version submitted for publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}